within Pharmacolibrary.Drugs.ATC.G;

model G01AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 2.0,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Inosine is a purine nucleoside formed by the deamination of adenosine. It has been used as a medication for various conditions, such as immunomodulation or neuroprotection, but it is not widely approved or in common use today. Its utility in clinical practice is limited and not supported by major regulatory agencies.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data are available for inosine in humans; the following parameters are estimates based on its structural similarity to adenosine and other nucleosides, as well as general pharmacokinetic principles.</p><h4>References</h4><ol><li>,Antiretroviral agents.,IARC monographs on the evaluation of carcinogenic risks to humans,2000<a href='https://pubmed.ncbi.nlm.nih.gov/11000975/'>https://pubmed.ncbi.nlm.nih.gov/11000975/</a></li><li>R Itoh,IMP-GMP 5'-nucleotidase.,Comparative biochemistry and physiology. B, Comparative biochemistry,1993<a href='https://pubmed.ncbi.nlm.nih.gov/8389266/'>https://pubmed.ncbi.nlm.nih.gov/8389266/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G01AX02;
